Beyond unfractionated heparin and warfarin: current and future advances.
about
Factor Xa inhibitors for acute coronary syndromesThe evolution of anticoagulant therapyUpdate on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceChemoenzymatic synthesis of heparan sulfate and heparinAnticoagulation drug therapy: a reviewDabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.The proof for new oral anticoagulants: clinical trial evidence.Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics CommitteesTriggers, targets and treatments for thrombosis.New options with dabigatran etexilate in anticoagulant therapyFactor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryChemoenzymatic synthesis of homogeneous ultralow molecular weight heparinsTravel-related thromboembolism: mechanisms and avoidance.Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.Probing structural selectivity of synthetic heparin binding to Stabilin protein receptorsBivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenationEvaluation of fibrinolytic medical therapy for patients with acute myocardial infarction.Analogs of N'-hydroxy-N-(4H,5H-naphtho[1,2-d]thiazol-2-yl)methanimidamide inhibit Mycobacterium tuberculosis methionine aminopeptidases.The design and synthesis of new synthetic low-molecular-weight heparins.The effect of anticoagulant pharmacotherapy on fracture healing.The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.Novel treatments for cardiovascular disease prevention.Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.Future of anticoagulant therapy.Old and new anticoagulant drugs: a minireview.Patient factors that influence warfarin dose response.Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.Inhibitors of propagation of coagulation: factors V and X.Newer oral anticoagulant agents: a new era in medicine.Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245.Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta-analysis of studies.Gender differences in the effects of cardiovascular drugs.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians.Bleeding hearts.Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy.Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
P2860
Q24234760-5E3D3EFA-9C05-4076-982C-9EC9DE60369CQ26771859-71362DF0-D572-4E10-AD4D-B292C5134326Q26782483-EA40D46B-EC36-4214-862C-07630FEEAA36Q27005958-29E0C070-2928-4470-BDE7-F559807A2D08Q27021871-874228F8-F937-47CE-BB43-B66E85308629Q33381801-73B6DFE3-004A-4FD8-BEB6-F2EF60F4D191Q33397016-0A57ED9B-6CDD-4BAA-AC0A-E6A9B77E9245Q33765274-51DDA6B3-185D-448E-A21C-AE04384729A0Q33765444-C5AE4AA0-80FA-4F0D-998D-6A64CAC6C4CCQ33888320-A77D3B26-46F1-47C1-8BFA-967AAAB6865DQ34128442-0632D0BF-A060-42F2-8C27-CBB7034C1F32Q34196711-725E8323-FA52-437D-8FA6-6135CBC71A3CQ34228210-DD41D18A-6955-42B7-90B5-337566DA7F2CQ34614374-1A048763-E124-4FE9-AEC1-369E472C423DQ35361517-5BF74F05-720C-4576-A2BE-731C1A7C7081Q36033096-0CDE6419-0F1D-4D3E-994A-D3FB680FA40DQ36073211-7DB791CB-928E-466C-BAA0-C655D6F27348Q36251591-66763F1A-508C-4A1F-82E8-AF2C0445822CQ36390383-76487CB3-F6E1-4252-86E2-73A67634C01FQ37004231-47C8370F-E214-4923-9B74-D134F20F4791Q37142069-EC25258D-D603-431F-9980-1FE03306A2F1Q37316352-33E8DB06-1C8C-4F5F-86EA-9B7A2131788FQ37428883-7175DD1D-81DA-422F-97BF-E000F2DF4591Q37548399-BCD9F19E-EF4F-4505-9262-DE64B6F16822Q37679209-2828637D-B2CC-434C-AC5B-94A09B0CD828Q37772194-98B08395-D847-4D26-BF3F-50EAB4F63C95Q37831332-6D40016A-F2F3-451B-800C-EFA4874C8AA5Q37867275-66334231-E58F-4E6A-97A6-90E76E1D940BQ37870757-1486A36F-B3CF-4131-B1FB-F91BC184DE6BQ37872338-9D73EF5E-A314-431B-A922-734DFA97E8DEQ38019591-52677F75-06AD-4961-8049-0F375ECEA915Q38251303-5A1F0A4F-03DF-4EF2-AFC3-13484E638F28Q38928208-DAFC4920-16C3-4D94-9DEB-50ABC2D80117Q39193538-78112FFF-7BAF-4AB8-931B-DE0BF3042B7CQ39213540-6A25A1E2-D634-4148-ADE7-8CA8D8DFD012Q39359007-1BA5F807-1C56-46E8-BB78-88A1AF69494AQ41205933-31C32461-D16F-4DD4-A59F-6BB02495F57AQ43196546-401FA9FF-17CB-473B-830B-0A390468767AQ44319954-2EF32668-2193-49ED-A3A9-A8000DDDBFF6Q46083556-A2581872-67DE-4577-ACB3-502E0B2C481A
P2860
Beyond unfractionated heparin and warfarin: current and future advances.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Beyond unfractionated heparin and warfarin: current and future advances.
@ast
Beyond unfractionated heparin and warfarin: current and future advances.
@en
Beyond unfractionated heparin and warfarin: current and future advances.
@nl
type
label
Beyond unfractionated heparin and warfarin: current and future advances.
@ast
Beyond unfractionated heparin and warfarin: current and future advances.
@en
Beyond unfractionated heparin and warfarin: current and future advances.
@nl
prefLabel
Beyond unfractionated heparin and warfarin: current and future advances.
@ast
Beyond unfractionated heparin and warfarin: current and future advances.
@en
Beyond unfractionated heparin and warfarin: current and future advances.
@nl
P1433
P1476
Beyond unfractionated heparin and warfarin: current and future advances.
@en
P2093
Jack Hirsh
P304
P356
10.1161/CIRCULATIONAHA.106.685974
P407
P577
2007-07-01T00:00:00Z